PATENT CLAIM ANALYSIS

Application Number: 16177165
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "188100"]

Abstract:
The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.

Claim (Index 5):
The HIV-1 vaccine immunogen of  claim 3 , wherein the T-helper epitope sequence is encapsulated within the nanoparticle.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 97.0
- Lexical Diversity: 2.125
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16176200', '15508885', '14806742', '14072209', '15075329']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7873576899636526
- 35 USC 102 Novelty (BERT): 0.5665330269965857
- Combined Prediction Score: 0.765275223666946
- Mean Citation Score: 385.3784480000001
- Max Citation Score: 485.73978
- Similarity Product: 344.3197536468423

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test